Viral and Prion Infections of the CNS – Cannabis THC : CBD Ratios

Viral and Prion Infections of the CNS Research Dashboard

5

Primary Studies

2

Related Studies

7

Total Studies

Clinical Studies

0

Double-blind human trials

0

Clinical human trials

Pre-Clinical Studies

1

Meta-analyses/Reviews

2

Animal studies

2

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 7 studies associated with Viral and Prion Infections of the CNS.

Here is a small sampling of Viral and Prion Infections of the CNS studies by title:


Components of the Viral and Prion Infections of the CNS Research Dashboard

  • Dosing information available for Viral and Prion Infections of the CNS
  • Chemotype guidance for treating Viral and Prion Infections of the CNS with cannabis
  • Synopsis of cannabis research for Viral and Prion Infections of the CNS
  • Individual study details for Viral and Prion Infections of the CNS

Ready to become a subscriber? Go to our PRICING page.

Select New Condition

Search By Keyword

Filter Condition

Members can filter by the following criteria:

  • Study Type
  • Chemotype
  • Cannabinoids & Endocannabinoids
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Viral and Prion Infections of the CNS

Description of Viral and Prion Infections of the CNS

Prions are misfolded (mal-shaped) proteins. Scientists consider prions to be infectious proteins responsible for Creutzfeldt-Jacob disease in humans, bovine spongiform encephalopathy (mad cow disease) in cows, and scrapie in sheep. Currently, all prion diseases are fatal. Prion diseases primarily affect the brain and central nervous system. The exact cause or mechanism by which prions misfold in the first place and how people acquire prion diseases remains the subject of ongoing debate and analysis. Some current findings focus on ingestion of prion-contaminated meat. It is thought that when a prion enters the organism it is able to alter the signals that produce newly formed proteins. The newly generated proteins fold into unhealthy shapes. While normally the body's own enzyme, protease, can digest old or diseased proteins, prions are resistant to the enzyme. These protease-resistant prion protein accumulations in the central nervous system are implicated in neuropathogenesis and prion infectivity. Once symptoms appear, degeneration is exponential. Most patients die within a year after the onset of symptoms.

Disease Classification

Condition: CNS Viral Infections
Disease Family: Infectious Disease (Prions)
Organ System: Nervous System
ICD-10 Chapter: Certain Infectious and Parasitic Diseases
ICD-10 Code: A81

Viral and Prion Infections of the CNS Symptoms:

Pain with swelling and redness, cognitive dysfunction (e.g. confusion, forgetfulness), behavioral difficulties (e.g. apathy, irritability), muscle twitching, ataxia (wobbly gait), loss of coordination, seizures

Also known as:

TSE, Prion Disease, Creutzfeldt Jakob disease, Subacute sclerosing panencephalitis, Progressive multifocal leukoencephalopathy

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example. 
  • THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), or beta-blockers (propranolol, theophylline, warfarin).  Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
  • Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

CBD Interaction with Pharmaceutical Drugs

  • CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
  • Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg (0.001mg/kg to 0.005mg/kg)
  • THC low dose:  0.5 mg to 5 mg (0.006mg/kg to 0.06mg/kg)
  • THC medium dose:  6 mg to 20 mg (0.08mg/kg to 0.27mg/kg)
  • THC high dose:  21 mg to 50+ mg (0.28mg/kg to 0.67mg/kg)
Formula for converting a set dose into mg/kg considerations: mg ÷ kg = mg/kg
(sample conversion calculated on a person weighing 75kg)

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg (0.005mg/kg to 0.25mg/kg)
  • CBD medium dose: 20 mg to 99 mg (0.26mg/kg to 1.32mg/kg)
  • CBD high dose:  100 mg to 800+ mg (1.33mg/kg to 10.7mg/kg)
  • (upper limits tested ~1,500mg)
Formula for converting a set dose into mg/kg considerations: mg ÷ kg = mg/kg
(sample conversion calculated on a person weighing 75kg)
Top

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.